GE HealthCare Launches New Handheld Ultrasound Device at ESC Congress
Featuring sector and linear arrays, the FDA-cleared Vscan Air SL ultrasound device reportedly enables cardiac and vascular assessments at the point of care.
Offering a combination of proprietary image enhancing technology and the ability to switch between vascular and cardiac assessments with one device at the point of care, GE HealthCare has launched the handheld ultrasound device Vscan Air SL at the European Society of Cardiology (ESC) Congress in Amsterdam, the Netherlands.
Emphasizing the proprietary SignalMax and XDclear technologies available with Vscan Air SL, GE HealthCare said the handheld ultrasound device offers enhanced sensitivity and resolution.
The dual-headed probe of Vscan Air SL also enables clinicians to access sector and linear arrays on the same device, a capability that facilitates rapid vascular and cardiac assessments of patients, according to GE HealthCare.
“Having ever more powerful handheld ultrasound is a game changer for patient care. Whether on the ward or in general practice, being able to provide high-quality imaging at the point of care means rapid diagnosis and rapid treatment,” noted Guy Lloyd, M.D., FRCP, a consultant cardiologist at Barts Heart Center and University College London Hospitals.
GE HealthCare noted that Vscan Air SL, which has garnered FDA 510(k) clearance, will be commercially available in the United States within the next month. The device is currently available in Austria and New Zealand as well as countries in Asia and Europe, according to the company.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
